iSGLT2
Phase 2Small molecule
iSGLT2 is one of 12 small molecule programs targeting Dialysis Patients. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Dialysis Patients
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Betadine
BBecton, Dickinson and Company
Approved
Sodium Valproate
AstraZenecaPhase 3
Evrenzo
AstellasPhase 2
KN060
SSuzhou Alphamab Co., Ltd.
Phase 2
Tirosint
IInstitut Jerome Lejeune
Preclinical
Deca-Durabolin
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
iSGLT2
MMaximo Agustin Schiavone
Phase 2
Tegopen
Bristol-Myers SquibbPreclinical
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iSGLT2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMaximo Agustin Schiavone